Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05223322 · ClinicalTrials.gov registry record · NA

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

A NA study of Breast Cancer, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
2
Study locations

NCT05223322: Recruiting NA study of Breast Cancer, sponsored by Medical College of Wisconsin.

NCT05223322 is a NA study of Breast Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05223322, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing and shotgun proteomics, have dramatically reduced the cost and technical challenge of accessing these tools for discovery-based research. Investigators are now able to obtain unbiased datasets showing changes in transcript or protein expression within complex samples. With cost and accessibility of sequencing is no longer being substantial bottleneck, one of major challenges researchers now face is determining how to meaningfully interpret profiles from large datasets. The extensive characterization of molecular pathways impacting inflammatory responses, endothelial function and angiogenesis, the pathway and network analysis tools will be an asset for identification molecular pathways relevant to alterations in microvascular endothelial function. The investigators preliminary studies on only a small number of samples highlights this potential of the proposed approach to lead to identify personalized medicine-based profiles that will predict patients are likely to develop microvascular endothelial dysfunction from CTx.

Primary Outcome

Investigators will use a graded protocol, starting at 50 watts followed by 30 watt increments every 2 minutes. Subjects will be connected to a breath-by-breath metabolic system (Cosmed, Italy) for measurement of VO2peak. A maximal effort will be defined as fulfillment of three of the following criteria: 1) A plateau in VO2 with an increase in work rate defined as an increase in VO2 of less than 50 ml/min; 2) A maximal HR within 10 beats of predicted maximal heart rate; 3) A respiratory exchange

Conditions Studied

Interventions

  • BEHAVIORAL Taking Charge during Treatment (TCT) Intervention

Study Locations (2)

Illinois

  • University of Illinois Chicago - Chicago

Wisconsin

  • Medical College of Wisconsin - Wauwatosa

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-03-01
Est. Completion 2026-07-01
Phase NA
Medical College of Wisconsin

447 total trials

What NCT05223322 shows while recruiting

NCT05223322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Taking Charge during Treatment (TCT) Intervention is the first listed.

NCT05223322 reports a single indexed study location in Illinois, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05223322 about?

NCT05223322 is a clinical study titled "Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction". Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained...

What is the current status of trial NCT05223322?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2022-03-01. Estimated completion is 2026-07-01.

What conditions does trial NCT05223322 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05223322?

The interventions under investigation include: Taking Charge during Treatment (TCT) Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05223322?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05223322 being conducted?

This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05223322's enrollment target sits among peer trials

80 649th of 1224 higher than 566 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05223322, the US trial registry maintained by the National Library of Medicine. NCT05223322 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.